| [1] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
| [2] |
DU Ying, XIE Yanming, WANG Lianxin, GENG Hongjiao, LI Xiangjie.
Clinical characteristics and drug combination analysis of Lianhua Qingwen capsules (granules) in the real world
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 296-300.
|
| [3] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|
| [4] |
HOU Tiantian, MA Sisi, WU Xiaobing, HUO Guitao, PAN Dongsheng, WANG Chao, XIA Yan, LIU Yi, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 19-26.
|
| [5] |
HOU Tiantian, XIA Yan, PAN Dongsheng, HUO Guitao, MA Xuemei, LIU Ziyang, SUN Li, LIU Yi, YAN Jian'ao, WU Xiaobing, ZHOU Xiaobing, LIU Guoqing, GENG Xingchao.
Toxicity of gene therapy drug AAV5-LPLS447X (GC304) in cynomolgus monkeys
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 27-33.
|
| [6] |
DONG Hanshuo, SUN Li, ZHAO Xiaoxiao, WANG Lianxin, YU Xiaokang, XIE Yanming.
Clinical characteristics and drug combination analysis of elemene injectable emulsion in the elderly in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 845-850.
|
| [7] |
YANG Fan, MA Haiping, YOU Mengru, LIAO Sha, LIU Lan, ZHU Jun.
Applications of antiviral drugs in 456 patients with COVID-19
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 413-416.
|
| [8] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
|
| [9] |
CHENG Xu, ZHANG Lidan, XIE Yanming, GAO Yang, YANG Yunyun.
Complex network analysis of combined medications of Danshen Ligustrazine injection in the treatment of coronary heart disease complicated with hypertension
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1325-1331.
|
| [10] |
LI Lingjun, TAO Lei, WEI Jun, LI Hongyang, CAI Baole, MA Pengcheng.
Effects of a single oral administration of finasteride tablets on bilirubin levels
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1202-1205.
|
| [11] |
LI Guowei, LI Likang, LIU Yingxin, WANG Ruoting, WU Darong.
Common problems related to P-value in observational pharmacoepidemiological studies
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 23-26.
|
| [12] |
HUANG Lihong, CHEN Feng.
Statistical considerations for real world studies supporting new drug registrations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 27-31.
|
| [13] |
LI Yiyun, LIAO Caiyun, PAN Jing, WEN Baoshu.
A Comparative Study of Chinese and American Orange Books Based on the 5W Model
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 806-809.
|
| [14] |
YAO Yamin, YAO Di, CHEN Yanqiu, LIU Li.
Clinical Characteristics of Shengmai Injection Based on the Hospital Information System in the Real World
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 876-879.
|
| [15] |
LIU Yuqiang, QIAO Rui, ZHUO Lin, MENG Ruogu, SUN Feng, ZHAN Siyan.
Ethical Risks of Real-World Data in Post-Marketing Drug Safety Studies
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 628-631.
|
